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Abstract
Background Concerns over the need to improve translational aspects of genetics research studies and engaging
community members in the research process have been
noted in the literature and raised by patient advocates. In
addition to the work done by patient advocacy groups,
organizations such as the Patient-Centered Outcomes
Research Institute advocate for a change in the culture of
research from being researcher-driven to becoming more
patient-driven.
Objective Our project, Autism Genetics and Outcomes
(AutGO), consists of two phases. The goal for phase I was
to initiate a general discussion around the main topic (i.e.,
linking genetics and outcomes research). We used the
Patient-Centered Outcomes Research Institute engagement
approach to: (aim 1) develop a partnership with a wide
range of stakeholders to assess their perspective on
developing projects that use both genetics and outcomes
research data/principles; (aim 2) identify barriers, facilitators, and needs to promote engagement in patient-centered
genetics research; and (aim 3) distill and describe actions
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that may facilitate utilization of patient/parent perspectives
in designing genetics research studies.
Methods In phase I, we formed a community advisory
board composed of 33 participants, including outcomes and
genetics researchers, clinicians, healthcare providers,
patients/family members, and community/industry representatives, and convened six sessions over the 12-month
period. We structured the sessions as a combination of
online PowerPoint presentations, surveys, and in-person
group discussions. During the sessions, we discussed topics
pertaining to linking genetics and outcomes research and
reviewed relevant materials, including patient stories,
research projects, and existing resources.
Results Two sets of surveys, project evaluations (k = 2)
and session evaluations (k = 6), were distributed among
participants. Feedback was analyzed using content analysis strategies to identify the themes and subthemes.
Herein, we describe: the established partnership (aim 1),
the identified barriers, facilitators, and needs (aim 2), as
well as the lessons learned and suggested recommendations for the research community (aim 3). Following
phase I participants’ recommendation, in phase II, we will
focus on a specific disease (i.e., autism); this projected
plan is briefly outlined to highlight the overarching goal
of the project and its potential significance. We also discuss the study limitations, challenges for conducting this
type of multidisciplinary work, as well as potential ways
to address them.
Conclusions The AutGO project has created a unique
collaborative forum to facilitate the much needed dialogue
between genetics and outcomes researchers, which may
contribute to finding ways to improve the translational
aspects of genetics research studies.
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Key Points
Currently, there is no systematic platform to gather
and process patient/parent perspectives and clinical
observations for research use (gap), therefore such
critical information is not commonly considered in
designing genetics studies.
Despite the recent emphasis on personalized
medicine, it is not yet clear how genetic information
may be used in patient-centered outcomes research,
in part owing to the lack of communication between
genetics and outcomes researchers.
The Autism Genetics and Outcomes (AutGO) project
aims to make a conceptual connection between the
two disciplines (outcomes and genetics research).
We outline how a partnership was established among
a wide range of stakeholders and report the findings
and recommendations for the research community.

1 Introduction
Recently, there has been a major push toward incorporating
patients’ voices in research studies with the goal of promoting research that addresses patients’ needs [1–3]. In
addition to the work done by patient advocacy groups [4],
organizations such as the Patient-Centered Outcomes
Research Institute (PCORI) [5, 6] advocate for a change in
the culture of research from being researcher-driven to
becoming more patient-driven.
There is also an emerging move toward using genetic
information in patient healthcare. In particular, the Precision Medicine Initiative [7] aims to take into consideration
an individual’s characteristics, including genetic make-up,
to personalize treatment [8]. Despite the recent emphasis
on precision medicine, it is not yet clear how genetic
information may be used in ‘‘patient-centered outcomes
research’’ (for simplicity, hereafter it will be referred to as
‘‘outcomes research’’). One of the main reasons why this
promising potential has been overlooked is the lack of
communication between genetics and outcomes researchers. This barrier could be addressed by developing a
practical engagement protocol to promote synergistic
relationships between the two respective disciplines.
Our project, Autism Genetics and Outcomes (AutGO),
consists of two phases. The goal for phase I was to initiate a
general discussion around the main topic (i.e., linking
genetics and outcomes research). The aims were to (1)
develop a partnership with a wide range of stakeholders to
assess their perspective and interest on creating projects that
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use both genetics and outcomes research data/principles, (2)
identify barriers, facilitators, and needs to promote engagement in patient-centered genetics research, and (3) distill and
describe actions that may facilitate utilization of
patient/parent perspectives in designing genetics research
studies. This paper outlines how a partnership was established and reports the findings (barriers, facilitators, and
needs) and recommended tasks distilled from the study
participants’ views. Following phase I participants’ recommendations, in phase II, we will focus on a specific disease
(i.e., autism); this projected plan is briefly outlined to
highlight the overarching goal of the project and its potential
significance. Considering the continuous nature of the two
phases, we chose AutGO as an overall project title to
emphasize the current and future direction of this initiative.

2 Background
2.1 Wealth of Existing Clinical/Genetic Resources
In the USA, PCORI [5] was established in 2010 to generate
research evidence to assist patients and providers in making informed health decisions by promoting patient-centered studies (i.e., focusing on questions that matter most to
patients). Other international initiatives, such as
INVOLVE, the UK-based program, also promote public
involvement in health research (http://www.invo.org.uk).
Traditionally, research hypotheses/questions have been
developed based on scientific facts and/or pilot data generated by researchers. As a result, patient concerns may not
directly influence the process. Alternatively, outcomes
studies intend to incorporate patient perspectives throughout the study, from the selection of the research questions
to the dissemination of the findings [1].
In addition to supporting comparative effectiveness
research (CER) and engagement projects, PCORI has also
invested in building research infrastructures by launching
PCORnet, a National Patient-Centered Clinical Research
Network [9, 10]. PCORnet combines electronic health
records and patient-generated data (i.e., clinical and research
networks led by patients, advocacy organizations, and clinical research partners), and may provide a valuable resource
for research purposes, if an opportunity is developed to
query the archived data. Recently, several disease-specific
networks partnered with PCORnet to use their existing
infrastructures to promote patient-centered research. Such
partnerships may reinforce using these resources in patientcentered studies. There are also non-PCORI resources,
including the eMERGE Network, a National Institutes of
Health-organized and funded consortium (http://emerge.mc.
vanderbilt.edu/) that combines DNA biorepositories with
electronic health records from patients.
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In addition to these disease-independent resources,
several disease-specific resources have been developed by
the research community. Data collections in the existing
resources need to be assessed to better understand to what
extent they may fulfill the data structure and capacity
required for testing patient-centered genetic questions.
2.2 Genetic Data and the Potential Application
in Outcomes Studies
The role of genetics in patient health outcomes cannot be
ignored because: (1) genetic factors contribute to the
underlying mechanism of most complex conditions, and (2)
it is well documented that drug metabolism and efficacy are
regulated by and dependent on a patient’s genetic make-up.
Research approaches using genetic information to
address a patient-centered question have been investigated
in some disciplines. Oncology and cardiology are two
fields where the importance of incorporating patient perspectives in improving medical care has already been
recognized, for example, in predicting patient outcomes
[11] or guiding treatment decisions [12]. It needs to be
explored how experiences gained in these conditions could
be applied to develop successful patient outcome predictors
for other conditions.

3 Methods
3.1 Ethics Statement
Ethical approval for this study to form an advisory board,
conduct focus groups, distribute surveys, and recruit to-bedetermined members was granted by the Office of
Research Integrity at our institution.
3.2 Partnership Formation and Focus Groups
A wide range of stakeholders were either involved from
inception or recruited at the beginning of the study. We
formed a community advisory board (CAB) composed of
33 participants, including genetics researchers, PCORI
awardees working on different conditions, bioinformaticists, physicians, patients/family members, and industry/community representatives. Furthermore, we invited
specialists involved in policy making, managing public
genetic databases, bioethics, and developing software for
managing patient data. See Tables S1 and S1a of the
Electronic Supplementary Material (ESM) for more details
on participants’ background/expertise.
We convened six sessions over the 12-month period.
During the sessions, we discussed topics pertaining to
linking genetics and outcomes research, and reviewed
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relevant materials (i.e., patient stories, research projects,
and existing resources). Feedback from CAB members was
collected and processed to identify barriers, facilitators,
and needs, as illustrated in Fig. 1. More details on methods,
research design, and data analysis are provided in Table S2
of the ESM, using the COREQ checklist [13].
We structured the sessions as a combination of online
PowerPoint presentations, surveys, and in-person group discussions (focus groups) to share educational materials with
CAB members and listen and learn from their experiences,
preferences, and needs in this context. This structure was
suggested by CAB members (when surveyed, 100% of participants approved it). We employed the principles of patient
engagement, community-based participatory research (i.e., by
equitably involving a wide range of stakeholders in all aspects
of our research process, including contributing expertise,
sharing decision making, and authorship), and a semi-structured iterative communication process (questionnaires/surveys) throughout all stages of the project.
Two sets of surveys, project evaluations, and session
evaluations were distributed using the SurveyMonkey tool
to obtain participants’ feedback. See the ESM for the list of
questions included in each survey.
Project evaluations (k = 2): The baseline project evaluation survey was conducted at the beginning of the study
and assessed the initial level of knowledge, attitudes, and
beliefs of the topic. The summative project evaluation
survey was conducted 11 months post-baseline to assess
the changes in knowledge and overall participants’ satisfaction at the end of the project.
Session evaluations (k = 6): We held six sessions
between the two project evaluations. Each session consisted of a PowerPoint presentation distributed by e-mail,
followed by a session evaluation survey, and concluded by
an in-person group discussion. Session evaluation surveys
were conducted to evaluate CAB members’ satisfaction
with the session quality and content. Results obtained from
each survey were discussed in subsequent in-person group
discussions (7–13 CAB members in each). Suggestions
were employed to improve the effectiveness and quality of
future sessions.
Responses obtained were compared and used as the
metrics to measure the study impact and significance.
Likert scale and free text responses were used to assess
participants’ responses obtained in surveys. A 0–10 point
scale was used to record a change of opinion (‘‘0’’ indicating ‘‘not changed at all’’ and ‘‘10’’ indicating ‘‘has
changed a great deal’’) between the two project evaluations
and/or level of agreement with given statements (‘‘0’’
indicating ‘‘strongly disagree’’ and ‘‘10’’ indicating
‘‘strongly agree’’) for session evaluations.
Feedback collected via surveys and other communication
means (see Fig. 1) was analyzed using content analysis
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Fig. 1 Schematic of the methods used in phase I. CAB community advisory board, CER comparative effectiveness research, PCORI PatientCentered Outcomes Research Institute

strategies [14]. Three coders (ABE, ZT, and AS) familiarized
themselves with the data, and identified and finalized the
themes and subthemes. Each coder independently coded the
data, then the coders met regularly to discuss and resolve discrepancies and reach consensus. After completion of standard
coding and content analysis, we further processed the study
findings from the perspectives of community engagement
(ABE) and scientists (ZT and AS). As a result, our approaches/
input were rather complementary in the further processing. For
example, ZT’s focus was tailored toward processing participants’ feedback and finding applicable ways to communicate
the identified results to the basic research community. ABE
focused on ensuring adequate community engagement
throughout the study process and dissemination plans.

Table 1 Demographic data: phase I

3.3 Project Website

Asian

n

%

Sex
Female

21

63.6

Male

12

36.4

30–39

11

33.3

40–49

5

15.2

50–59

10

30.3

60–69

2

6

Skipped question

5

15.2

28
3

84.8
9.1

2

6.1

Age (years)

Race
White/Caucasian
Black/African American
Education level

The project website (http://genetics-outcomes.net/AutGOPhaseI) was developed under the principal investigator’s
supervision with input from study participants. It was used
to archive a summary of all communications, meeting
minutes, and related documents. Participants were granted
access to the website to allow them to review progress and
give feedback at their convenience.

4 Results
4.1 Summary: Tasks and Findings
Thirty-three participants took part to assess if/how genetic
information may be used in outcomes studies. Eighteen

Bachelor’s degree

10

30.3

Master’s degree

3

9.1

Professional degree

1

3

19

57.6

Doctorate degree

CAB members had been recruited and engaged from
inception. ZT, SB, AS, and KS developed the original
research plan. ABE and AM were involved in further
refinement of the research plan and designing a community
outreach protocol. To-be-determined members (n = 15)
were identified and recruited by existing members through
professional/community/personal contacts. See Table 1 and
Table S1 of the ESM for participants’ demographic data and
background with respect to contribution to the project. The

Autism Genetics and Outcomes (AutGO)
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Table 2 Disease of interest per stakeholder category: phase I
Disease of interest

Stakeholder category
Parents/patients

Physicians

Mean (total)* (%)
PCORI awardees

Bioinformaticists

Scientists

Others
5 (71.4%)

1. Autism

4 (33.3%)

1 (11.1%)

1 (25%)

8 (53.3%)

2. CVD

4 (33.3%)

4 (44.4%)

3 (50%)

2 (50%)

3 (20%)

3. Cancer

6 (50%)

3 (33.3%)

3 (50%)

1 (25%)

4 (26.7%)

39.40
27.30

1 (14.2%)

4. Other

27.30
27.30

Details for ‘‘Other’’ disease category
Turner syndrome

1 (8.3%)

Metabolic disease
Rehabilitation medicine

1 (8.3%)
1 (11.1%)

Nephrology

1 (11.1%)

Infectious Diseases

1 (11.1%)

1 (6.7%)
1 (16.7%)

Research Informatics

1 (6.7%)
1 (25%)

1 (6.7%)

Sleep disorders

1 (6.7%)

Genetics

1 (6.7%)

1 (14.2%)

Bipolar disorder

1 (14.2%)

ADHD

1 (14.2%)

Allergies

1 (14.2%)

Asthma

1 (14.2%)

Numbers and percentages are shown per each stakeholder category
ADHD attention-deficit hyperactivity disorder, CAB community advisory board, CVD cardiovascular disease, PCORI Patient-Centered Outcomes
Research Institute
*The average total was calculated based on the total number of CAB members (N = 33). Of note, some CAB members selected more than one
disease category

CAB consisted of the following groups of stakeholders
(63.6% female, 84.8% Caucasian): parents/patients 36.4%
(n = 12); physicians 27.3% (n = 9); PCORI awardees
18.2% (n = 6); bioinformaticists 12.1% (n = 4); scientists
45.5% (n = 15); and others 21.2% (n = 7).
In the baseline survey, we asked participants to identify
their disease of interest, as shown in Table 2 and Table S1
of the ESM. Corresponding numbers and percentages were
calculated separately per each stakeholder category. Some
members selected more than one disease category; however, autism was selected as a priority topic by 39.4% of
participants.
Feedback from participants indicated their high level of
interest on the topics covered, willingness to share personal
experiences and to learn other stakeholders’ perspective, as
well as appreciation for the educational aspect of the project.
Topics covered were carefully selected to provide a meaningful overview of the most relevant areas, considering participants’ diverse backgrounds. Successful implementation of
this aspect (100% approved by participants) was monitored
via surveys, as exemplified in Table 3. See Tables S3 and S4
of the ESM for more details on participants’ assessment of
topics covered per stakeholder category.
Questions in the baseline and summative surveys (called
Qa and Qb, respectively), assessed knowledge gained by

participants pertaining to key topics (PCOR/CER and
genetics), are summarized in Table 4. Some participants
were already familiar with PCOR/CER concepts prior to
being involved with the AutGO project, whereas others had
no previous knowledge. Therefore, responses related to the
questions Q1a (I am familiar with PCOR and CER) and
Q1b (How much has your knowledge about PCOR and
CER changed?) were divided into two groups: Group 1
(n = 16) had limited experience with PCOR/CER [average
5.6 (standard deviation [SD] 1.9) for Q1a; on a 0–10 point
scale] at baseline, and reported significant knowledge gain
[average 7.9 (SD 1.1) for Q1b] at the end. In contrast,
Group 2 (n = 17), reported a high level of experience with
PCOR/CER at baseline [average 9.4 (SD 0.9) for Q1a].
Nevertheless, they acknowledged a moderate change [average 6.8 (SD 2.1) for Q2b] in their perspective/knowledge
about this topic as a result of participation in the study.
Three sets of questions (Q2a,b; Q3a,b; Q4a,b) were used
to assess knowledge/interest about using genetic information in outcomes research. Average scores for baseline and
summative questions are shown in Table 4. Four respondents who reported a prior high level of knowledge/interest
of genetics, interpreted summative assessment questions
differently than the rest of the respondents. Because they
have already reported a high level of interest (average 10)
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Table 3 Participants’ assessment of topics covered: phase I
Mean (SD*)
Participants’ personal perspectives
Topic
Familiarity with PCOR and CER

7.9/10 (1.5)

Importance of incorporating genetic information into CER

8.0/10 (0.5)

Interest level in using genetic information in CER studies

7.9/10 (0.6)

Participants’ assessment of educational aspect of the project
Approval of the topics covered
Overall clarity of presentations

100%
8.8/10 (0.4)

Topics with the highest ratings
Patient personal stories

9.3/10 (1.1)

Examples of electronic medical record systems

8.9/10 (1.1)

Overview of the ethical issues and genetic testing

8.8/10 (1.0)

Overview of existing resources (PCORnet, eMERGE)

8.8/10 (1.0)

Examples of genetic research done by our CAB members (scientists)

8.8/10 (1.3)

Precision Medicine Initiative

8.8/10 (1.2)

Participants’ responses are based on a scale from ‘‘0- Strongly disagree’’ to ‘‘10- Strongly agree’’
CAB community advisory board, CER comparative effectiveness research, SD standard deviation, PCOR patient-centered outcomes research
*SD equals the mean SD across groups
Table 4 Participants’ assessment of two key topics [patient-centered outcomes research/comparative effectiveness research (PCOR/CER) and
genetics]: phase I
Survey
topics

Baseline (Qa)

CER/
PCOR

Q1a. I am familiar with PCOR and CER

Questions

Summative (Qb)
Mean
(SD)

Questions

n
Mean
(SD)

Q1b. How much has your knowledge about PCOR and CER
changed?

Group
1*

5.6
(1.9)

7.9
(1.1)

16

Group
2**

9.4
(0.9)

6.8
(2.1)

17

Genetics
Q2a. I find it important to incorporate
genetic information into CER

8.1
(2.1)

Q2b. How much has your opinion on ‘‘the importance of
incorporating genetic information into outcomes research’’
changed?

8.4
(1.7)

29

Q3a. I have a clear understanding of how
genetic information may be incorporated
in CER

6.1
(1.8)

Q3b. How much has your understanding of ‘‘how genetic
information may be incorporated in PCOR and CER’’
changed?

8.2
(1.2)

29

Q4a. I am interested in using genetic
information in CER studies

8.2
(1.6)

Q4b. How much has your interest in using genetic
information in PCOR and CER studies changed?

8.2
(1.7)

29

n number of responses, SD standard deviation
*Limited experience with PCOR/CER prior to participation in phase I
**High level of experience with PCOR/CER prior to participation in phase I

at the baseline, in the summative assessment, they only
acknowledged that their interest level remained the same,
instead of reporting changes. Therefore, results for questions related to the use of genetic information (Q2a,b;
Q3a,b; Q4a,b) were adjusted by removing these four

responses (n = 29 out of 33). Of note, responses to Q3b
(How much has your understanding of ‘‘how genetic
information may be incorporated in PCOR and CER’’
changed?), which reflects the main objective of the AutGO
project, clearly shows an increase [from average 6.1 (SD

Autism Genetics and Outcomes (AutGO)
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1.8) for Q3a to 8.2 (SD 1.2) for Q3b] in the participants’
level of understanding of this topic as a result of participation in the study.

These lessons learned can be taken into consideration for
future studies.
1.

4.2 Participant Feedback
The general themes identified by CAB members, reflecting
barriers, facilitators, and needs (i.e., for if/how genetic
information may be used in outcomes studies), are summarized in Table 5. For example, 16 participants reported
difficult subject matter (subtheme 1.1.3). See Table 6 for
examples of actual quotes.
4.3 Lessons Learned

2.

3.

Based on our experience from working with participants
with diverse backgrounds and expectations, we learned that
some elements may enhance study participants’ contribution and overall implementation of the results (see Fig. 2).

4.

Many useful resources containing genetic/clinical data
have already been developed, but study participants,
including scientific/clinical members, may not be
aware of them. Familiarizing stakeholders with such
resources would promote the development of studies
that use both genetics and outcomes research data/
principles.
Setting reasonable expectations for study participants
is needed to maintain each member’s meaningful
contribution without slowing down the overall
research process.
Study participants’ motivation and time devotion are
essential in reviewing the provided educational
materials.
Reviewing practical research examples would facilitate a better understanding of the topic, particularly,
for non-technical study participants.

Table 5 Barriers, facilitators, and needs identified based on participants’ perspectives (phase I): themes and subthemes
Themes
1. Barriers

1.1. Limited knowledge

1.2. Ethical issues
1.3. Logistical issues

2. Facilitators

3. Needs

Subthemes

Qty

1.1.1. Provider limited knowledge/training

3

1.1.2. Patient/community limited knowledge

9

1.1.3. Difficult subject matter/information too dense

16

1.2.1. Ethical concerns

2

1.2.2. Stigma

3

1.3.1. Insufficient patient/parent engagement

1

1.3.2. Insufficient resources/genetic counselors

1

1.3.3. Technical challenges/EMR/internet access

4

1.3.4. Logistical challenges

3

1.4. Other

1.4.1. Cost/insurance coverage

1

2.1. Knowledge/training

1.4.2. Other
2.1.1. Knowledge/awareness/information

1
8

2.1.2. Providing training

1

2.2. Establishing partnership

2.2.1. Collaborative environment

4

2.2.2. New/future research priorities

1

2.3. Other

2.3.1. Improve care/health outcomes

3

3.1. Education
3.2. Engagement

2.3.2. Easy/Interactive presentation style /videos

8

3.1.1. Providing education

4

3.1.2. Easy to understand and interactive resources/glossary

13

3.2.1. Patient/parent engagement/more overall interaction

6

3.2.2. Social and media outreach

2

3.2.3. Future research collaboration

2

3.3. Infrastructure

3.3.1. Developing Infrastructures (linking clinical and research works)

1

3.4. Other

3.4.1. Patient-centered

3

3.4.2. General comments about project

17

3.4.3. Other

3

EMR electronic medical records, Qty number of times a given subtheme was noted in participants’ feedback
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Table 6 Example of stakeholder quotes grouped based on the identified themes/subthemes
Subthemes*

Stakeholder category**: Example quotes

1.1.2

Patients/Parents: ‘‘More personal interaction would be helpful. I think there is some additional benefit to be gained by
interaction between the presenter and audience.’’

1.1.2 and 3.1.1

Scientists/Bioinformaticists: ‘‘Patients and families can help this study by sharing a list of questions they have about the
condition, their concerns and worries, related to possible prevention or treatment protocols and so on.’’

1.1.2 and 3.1.1

Scientists/Bioinformaticists: ‘‘I would consider providing patients/families with the resources that they can learn about
the disease condition and related risk factors or in general raising awareness related to genetic diseases and risk factors
is as a prerequisite (for participation in such projects).’’

1.1.3 and 3.1.2

PCORI awardees: ‘‘Visual representation is often helpful in explaining complex context. Otherwise, poor level of
understanding may be intimidating for lay people.’’

1.1.2 and 1.1.3 and
3.1.2

Patients/Parents: ‘‘Investigators do not have time to make a conversion of terminology to bring us (patient members)
along with them. It will remain a big obstacle until they come up with some systematic approach.’’

1.2.1 and 1.2.2

Scientists/Bioinformaticists: ‘‘It would also be great to talk about fear that people have about having EMR, the same as
about genetic testing, regarding who exactly will be able to see the data. How much protection the patients have,
considering sometimes tricky language in consent forms?’’

1.2.1 and 1.2.2

Physicians/Scientists: ‘‘There is often lack of communication and explanations between medical field and patients,
which produces misinterpretations and lack of trust.’’

1.2.1 and 1.3.4

Patients/Parents: ‘‘I found the genetic research tied to autism of great interest to me both as a parent as well as a
provider. We have often discussed the implication of autism like symptoms that exist in our girls with Turner
Syndrome (TS). Sleep disturbances are common in our TS population. The discussions (about sleep problems in
autism) make me wonder if we are seeing the same subset of problems (in TS).’’

1.3.2

Scientists/Bioinformaticists: ‘‘Number of genetic counselors is insufficient. We cannot expect genetic counseling to be
done by basic physicians, they are not geneticists.’’

1.3.2

Patients/Parents: ‘‘Whose responsibility will it be to review the genetic information gathered about a patient as he/she
grows older? Will the patient have to remember that they had genetic information obtained?’’

1.3.3 and 1.4.1

Patients/Parents: ‘‘There are challenges, like data being collected based on different platform that makes integration
difficult. It brings along additional expenses for hospitals to be able to share patients’ data between health care
providers.’’

1.4.1

Physicians: ‘‘In clinical practice I frequently have parents who want to do genetic testing but have trouble obtaining prior
authorization from insurance companies to cover testing which is often quite expensive.’’

2.1.1

Physicians: ‘‘So far the information has been really helpful! I’m learning so much about PCORI and PCORnet. Very
exciting!’’
Physicians/Scientists: ‘‘I have enjoyed the patient experience formats. It is great to hear a perspective from a fellow
scientist who has had a family member affected by genotypic variations.’’

2.2.1
2.2.1

Physicians/Scientists: ‘‘Especially loved being able to interact with patients and their families and to hear their
opinions.’’

2.2.2 and 2.3.1

PCORI awardees: ‘‘The definition and description of PCORnet was extremely helpful in providing a framework for how
we researchers could access genetic data and incorporate it in research to improve health outcomes.’’
Scientists/Bioinformaticists: ‘‘With regard to having collaborators on this study from different time zones and
schedules, I think PowerPoint presentations are very useful and convenient.’’

2.3.2
2.1.1 and 3.4.2

Physicians: ‘‘eMERGE seems like it is a great opportunity. I was not aware of this project previously.’’

2.1.1 and 3.4.2

Industry representatives: ‘‘I was not aware of the information about drug resistance (and genetic risk factors).’’

3.1.1

Scientists/Bioinformaticists: ‘‘Providing educational materials about environmental risk factors.’’

3.1.2

Patients/Parents: ‘‘A glossary would be nice to have, or connect to other sources that may have already been
developed.’’

3.1.2

Scientists/Bioinformaticists: ‘‘Would be good to have a summary slide with the most important features of these
initiatives (eMERGE, PCORnet) and how these compare to one and other. The same comment applies to information
shared about technologies and health record systems.’’

3.2.1

PCORI awardees: ‘‘With respect to future disease specific project, may be useful to take an opportunity to get input
beyond this group, from providers in the hospital and the community, patients and researchers.’’

3.2.2

PCORI awardees: ‘‘What if we give more visibility to the project website? Can we open it up and make it accessible for
the public and make it more interactive to be able to reach out to people doing similar type of work? People could find
each other, initiate potential collaborations, collect additional feedback.’’

Autism Genetics and Outcomes (AutGO)
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Table 6 continued
Subthemes*

Stakeholder category**: Example quotes

3.2.3

PCORI awardees: ‘‘There are many different hospitals engaged in that network (PCORI funded Greater Plains
Collaborative project). Do they include any genetic data? For future, when they have the infrastructure established, it
would make sense if they added a genetic component.’’

3.4.2

Scientists/Bioinformaticists: ‘‘Having the actual findings from eMERGE phase I and II would be helpful – and/or a list
of publications that were a result of the effort. Same comment maybe for PCORnet.’’

CAB community advisory board, PCORI Patient-Centered Outcomes Research Institute, EMR electronic medical records
*Themes/subthemes are listed in Table 5
**Some CAB members represented more than one stakeholder category

Fig. 2 Study aims and findings in phase I. CAB community advisory board

5.

6.
7.

Visual aids (e.g., videos, webinars, and illustrations)
are great educational tools and help with explaining
complex contexts.
Hearing patients’ stories help researchers frame the
explanatory materials.
Focusing on one disease would be helpful for:
developing practical example(s) that link genetics
and outcomes research; stimulating interest for stakeholders to participate in a genetics outcomes study;
identifying more specific barriers and needs, as well as
implementing results among the research community.

4.4 Suggested Recommendations for the Research
Community
The unique composition of our CAB provided us with a
rare opportunity to assess the study findings in a complementary manner, from both outcomes and basic research

standpoints. Not only did it enable us to use principles of
qualitative assessments, but also allowed us to further
process the study findings and distill actionable recommendations that would facilitate their implementation. As a
result of applying this complementary assessment, we
suggest the following recommendations/tasks:
4.4.1 Building Genetics and Outcomes Multidisciplinary
Teams
We refer to integrated research approaches that use data
and principles of both genetics and outcomes research as
GO projects. Unlike other multidisciplinary approaches,
building a team for a GO project, in addition to the
inclusion of different expertise, requires further considerations. It is essential to maintain patient centeredness
throughout the process of GO team building. This notion
should be considered in defining study team composition
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(both technical and non-technical members); furthermore,
all members must either have a prior experience with or a
willingness to adopt a patient-centered approach; i.e., be
vigilant about the overall goal (improving patient outcomes, NOT identifying disease causality). Owing to the
multidisciplinary nature of GO projects, in addition to
patient involvement, they also imply a bi-directional
approach: developed by incorporating genetic information
into outcomes studies and/or bringing the outcomes
research approach into genetics studies.

pitfall for conducting queries on multiple resources (i.e.,
de-identified electronic health records, and/or diseasespecific databases) is the incompatibility of their informatics platforms. Addressing this technical obstacle could
facilitate such assessments and stimulate more effective
engagement and contribution of participants, especially
non-technical members, throughout the study process.

4.4.2 Raising Awareness in the Research Community

5.1 Development of an Autism-Specific Educational
Protocol (Phase II)

Despite a growing interest among different groups of
stakeholders, it appears that the research community is not
fully aware of the need to promote developing GO projects.
To stimulate interest towards developing patient-centered
genetics research projects, awareness needs to be raised
among the research community about GO studies, and
patient-powered resources such as PCORnet, as well as
initiatives such as the AutGO project. This would encourage the research community to consider developing projects that prioritize translational aspects of the study over
finding genetic causes.
4.4.3 Developing Effective Educational Protocols
A combination of online courses, website postings, and inperson meetings/workshops can be used to design an
educational protocol with the aim of motivating the
research community to consider developing GO projects.
4.4.4 Developing Disease-Specific Examples
We identified several key issues on the general topic of
linking genetics and outcomes research. To build a more
detailed engagement and implementation plan, diseasespecific projects need to be developed. Focusing on a given
disease will enable the implementation of lessons learned
from such engagement activities to establish research
partnerships with the relevant stakeholders. Step-by-step
instructions for a practical workflow and potential gaps
(i.e., patient/community engagement, hypothesis development, data retrieval from genetic/phenotypic databases, and
statistical analysis) pertaining to each condition could be
crafted by developing disease-specific research examples.
4.4.5 Assessing Existing Resources
To identify to what extent patient-centered questions could
be addressed using the genetic/clinical data archived in the
existing resources (e.g., PCORnet and eMERGE), they
need to be assessed by a GO team. One potential technical

5 Future Directions

In phase II, we will apply lessons learned from phase I to
develop a disease-specific educational protocol. Autism
was selected as the disease of interest based on the following: (1) this condition has a strong genetic basis, and
developing GO studies may have a profound impact on
improving health-related decisions for this patient population, (2) the majority of phase I members (39.4%) identified autism as a disease of interest (as a parent, healthcare
provider, scientist, or industry representative), and (3) a
rapidly growing amount of genetic information has been
generated from subjects with autism. Furthermore, mental
health is among PCORI’s top priority conditions, resulting
in a major investment in autism in outcomes research,
including the recent partnership of PCORnet with two
autism-related networks, Interactive Autism Network and
Phelan–McDermid syndrome.
To develop a practical autism-specific protocol, first, a
GO team has to be built to develop a hypothesis for autism
that fits with both outcomes and genetics research. One area
where patient engagement could be crucial is the identification of environmental risk factors, which may help
develop a research hypothesis related to gene–environment
interactions, a largely unknown area of research that also
carries a considerable potential to identify meaningful outcomes for improving patient health. Another avenue for
selecting research priorities to be assessed by a GO team
would be via findings from other studies on this topic,
conducted with input from patients with autism.
Subsequently, the genetic/phenotypic data archived in
the existing autism-specific and non-autism resources need
to be evaluated to establish to what extent they can be used
to assess the identified patient-centered research hypothesis, as well as relevant limitations. The success and impact
of new initiatives such as the AutGO project depend on the
involvement of a larger autism research community. One
effective method of raising awareness would be through
organizing educational workshops around this topic, particularly, at the scientific meetings such as the International
Society for Autism Research.

Autism Genetics and Outcomes (AutGO)

A lack of translational aspects and an often inadequate
inclusion of patient concerns/priorities in the work process
is a recognized gap in many conditions, including autism.
Several autism genetic initiatives have been formed with
the overall goal of identifying causality, leading to
important gene discoveries. However, the overarching goal
of the AutGO initiative is on developing genetics research
questions aimed at addressing outcomes, NOT finding
genetic causes. This may sound a laudable goal, but by
setting patient centeredness and outcomes, NOT causality,
as the main goal, we feel the AutGO project may bring
more attention to this critical existing gap and serve as an
effort complementary to other autism genetic initiatives.

6 Limitations
Owing to the time constraints and budget restrictions, we
gave priority to recruiting local participants. As a result,
several participants were our institution employees (i.e.,
clinicians and parent representatives). Therefore, our findings/recommendations may not be viewed as a comprehensive and uniform representation of the local community
perspectives, particularly with respect to minority groups
and hard-to-reach participants. This limitation could be
addressed by informing and engaging a wider community,
which could be facilitated through this publication. During
survey analysis, we noticed that using more specific rating
scales in certain questions would have reduced potential
confusion for interpretation (e.g., anchor the 0–10 ratings
as ‘‘increased’’ rather than ‘‘changed’’ because the latter
does not imply a direction).
A potential challenge to this as well as other patient and
community engagement projects is the real or perceived
imbalance of power between study participants, particularly, technical and non-technical members. We prepared a
memorandum of agreement that outlined the roles and
responsibilities of each member to make communication
more open, honest, and transparent. Providing training and
ongoing follow-up support may be beneficial to further
ensure inclusive involvement of all participants, particularly more dynamic engagement of patients/family members. Another potential challenge is to ensure patient
centeredness in GO studies. This aspect cannot be reached
without tangible patient engagement throughout the study.
For our project, patient engagement was evaluated by the
funding agency through a strict monitoring process
including regular/monthly reports, which facilitated
addressing this challenge. Another way to reinforce this
aspect would be through involvement of outcomes experts/
PCORI investigators experienced in conducting patientcentered studies, when forming GO teams. Other areas for
further investigation, which are beyond the scope of our

461

work, include: ethical issues related to using genetic
information for improving patient outcomes and effective
communication methods for multidisciplinary work.

7 Conclusions
The principles of conducting outcomes studies, such as
patient involvement in every aspect of the process, have
been well defined elsewhere [3, 15] and are intrinsic elements of the AutGO project. However, a lack of communication between genetics and outcomes researchers is a
unique gap pertaining to conducting GO projects; therefore, to address this gap, we are targeting the research
community as a main audience for this paper. To make a
connection between genetic information and patient-centered studies, in addition to engaging patients in the process, the research community, particularly, the genetics
research community needs to: (1) be aware of the communication gap and (2) dynamically participate in relevant
dialogues to become an active partner in designing/conducting GO projects. One effective method of stimulating
interest in developing this type of unique collaborative
effort is to educate stakeholders about why and how team
members may work in synergy on developing GO projects.
This process may involve (1) developing disease-specific
educational protocols that integrate relevant concepts (e.g.,
patient centeredness and translational elements) and
demonstrate their applicability at different stages of the
study process, (2) identifying potential connections
between outcomes research and genetic information, and
(3) assessing the potential applicability of the existing
phenotypic/genotypic data in this context. Our motivation
in developing the AutGO initiative is to create a hybrid
concept connecting the outcomes and genetics disciplines
to demonstrate the potential and benefits of interplay
between them, which may facilitate dialogue for finding
practical ways to take into consideration patients/parents
perspectives when designing GO studies.
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